Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 20;12(8):1900.
doi: 10.3390/biomedicines12081900.

Diabetes and Its Impact on Cardiogenic Shock Outcomes in Acute Myocardial Infarction with Polyvascular Disease: A Comparative Analysis

Marlon V Gatuz  1 , Rami Abu-Fanne  1 , Dmitry Abramov  2 , Mamas A Mamas  3   4 , Ariel Roguin  1 , Ofer Kobo  1   3
Affiliations

Diabetes and Its Impact on Cardiogenic Shock Outcomes in Acute Myocardial Infarction with Polyvascular Disease: A Comparative Analysis

Marlon V Gatuz et al. Biomedicines. .

Abstract

Background: Diabetes mellitus (DM) significantly impacts cardiovascular outcomes, particularly in patients with acute myocardial infarction (AMI) complicated by cardiogenic shock (CS). The presence of polyvascular disease further complicates the prognosis due to the increased burden of atherosclerosis and comorbidities. This study was designed to investigate the combined impact of DM and polyvascular disease on outcomes in patients with AMI and CS.

Method: Using the National Inpatient Sample database, we analyzed 39,140 patients with AMI complicated by CS and known polyvascular disease. The patients were stratified by diabetes status. The study assessed in-hospital major adverse cardiovascular and cerebrovascular events (MACCE), mortality, cerebrovascular accident (CVA) and major bleeding. Multivariable logistic regression models were used to examine the association between in-hospital outcomes and diabetes, adjusting for baseline differences.

Results: Of the study population, 54% had DM. The patients with DM were younger (69.5 vs. 72.1 years, p < 0.001) and more likely to be female (36.7% vs. 34.2%, p < 0.001). After adjustment, the patients with DM showed a 17% increased mortality risk (aOR 1.17, 95% CI: 1.11-1.23, p < 0.001) and a higher risk of major adverse cardiovascular and cerebrovascular events (aOR 1.05, 95% CI: 1.01-1.10, p = 0.020).

Conclusions: DM significantly impacts outcomes in patients with AMI complicated by CS and polyvascular disease, leading to increased mortality risk, longer hospital stays, and higher healthcare costs. These findings underscore the need for targeted interventions and specialized care strategies for this high-risk population.

Keywords: acute myocardial infarction; cardiogenic shock; diabetes mellitus; outcomes; poly-vascular disease.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Flow Diagram.
Figure 2
Figure 2
Disposition of patients based on diagnosis of diabetes.
Figure 3
Figure 3
Adjusted odds ratio for in-hospital procedure complications in acute myocardial infarction patients with diabetes mellitus and polyvascular disease complicated by cardiogenic shock. Reference: no DM; adjusted for age, gender, hospital bed size, region and location/teaching status, STEMI, CABG, PCI, angiography, thrombolysis, mechanical ventilation, circulatory support, VF, VT, AF, HF, hypertension, valvular heart disease, smoking status, chronic liver disease, anemia, thrombocytopenia, coagulopathies, and malignancies.
See this image and copyright information in PMC

References

    1. Grundy S.M., Benjamin I.J., Burke G.L., Chait A., Eckel R.H., Howard B.V., Mitch W., Smith S.C., Jr., Sowers J.R. Diabetes and cardiovascular disease: A statement for healthcare professionals from the American Heart Association. Circulation. 1999;100:1134–1146. doi: 10.1161/01.CIR.100.10.1134. Erratum in Circulation 2000, 101, 1629–1631. - DOI - PubMed
    1. Leon B.M., Maddox T.M. Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. World J. Diabetes. 2015;6:1246–1258. doi: 10.4239/wjd.v6.i13.1246. - DOI - PMC - PubMed
    1. Samsky M.D., Mentz R.J., Stebbins A., Lokhnygina Y., Aday A.W., Pagidipati N.J., Jones W.S., Katona B.G., Patel M.R., Holman R.R., et al. Polyvascular disease and increased risk of cardiovascular events in patients with type 2 diabetes: Insights from the EXSCEL trial. Atherosclerosis. 2021;338:1–6. doi: 10.1016/j.atherosclerosis.2021.10.011. - DOI - PMC - PubMed
    1. Gutierrez J.A., Scirica B.M., Bonaca M.P., Steg P.G., Mosenzon O., Hirshberg B., Im K., Raz I., Braunwald E., Bhatt D.L. Prevalence and Outcomes of Polyvascular (Coronary, Peripheral, or Cerebrovascular) Disease in Patients With Diabetes Mellitus (From the SAVOR-TIMI 53 Trial) Am. J. Cardiol. 2019;123:145–152. doi: 10.1016/j.amjcard.2018.09.014. - DOI - PubMed
    1. Kobo O., Cavender M.A., Jensen T.J., Kuhlman A.B., Rasmussen S., Verma S. Once-weekly semaglutide reduces the risk of cardiovascular events in people with type 2 diabetes and polyvascular disease: A post hoc analysis. Diabetes Obes. Metab. 2023;11:1129–1132. doi: 10.1111/dom.15396. - DOI - PubMed

LinkOut - more resources